Published in Antimicrob Agents Chemother on June 01, 2000
Histoplasmosis: a clinical and laboratory update. Clin Microbiol Rev (2007) 6.41
In vitro fungicidal activities of voriconazole, itraconazole, and amphotericin B against opportunistic moniliaceous and dematiaceous fungi. J Clin Microbiol (2001) 2.13
Clinical and laboratory update on blastomycosis. Clin Microbiol Rev (2010) 2.01
Population pharmacokinetic analysis of voriconazole plasma concentration data from pediatric studies. Antimicrob Agents Chemother (2008) 1.79
Testing conditions for determination of minimum fungicidal concentrations of new and established antifungal agents for Aspergillus spp.: NCCLS collaborative study. J Clin Microbiol (2002) 1.72
Melanization of Cryptococcus neoformans and Histoplasma capsulatum reduces their susceptibilities to amphotericin B and caspofungin. Antimicrob Agents Chemother (2002) 1.57
In vitro susceptibilities of Madurella mycetomatis to itraconazole and amphotericin B assessed by a modified NCCLS method and a viability-based 2,3-Bis(2-methoxy-4-nitro-5- sulfophenyl)-5-[(phenylamino)carbonyl]-2H-tetrazolium hydroxide (XTT) assay. Antimicrob Agents Chemother (2004) 1.39
Voriconazole use for endemic fungal infections. Antimicrob Agents Chemother (2009) 1.10
Update on the optimal use of voriconazole for invasive fungal infections. Infect Drug Resist (2011) 0.95
Successful use of voriconazole for treatment of Coccidioides meningitis. Antimicrob Agents Chemother (2004) 0.87
Successful use of combination antifungal therapy in the treatment of coccidioides meningitis. J Natl Med Assoc (2006) 0.86
In vitro effect of sulfamethoxazole-trimethoprim against Histoplasma capsulatum var. capsulatum. Antimicrob Agents Chemother (2010) 0.82
Antifungal therapeutics for dimorphic fungal pathogens. Virulence (2016) 0.81
Quantitative Microplate-Based Growth Assay for Determination of Antifungal Susceptibility of Histoplasma capsulatum Yeasts. J Clin Microbiol (2015) 0.79
Synergistic effect of antituberculosis drugs and azoles in vitro against Histoplasma capsulatum var. capsulatum. Antimicrob Agents Chemother (2011) 0.78
Fusarium peritonitis successfully managed with posaconazole and catheter removal. Perit Dial Int (2014) 0.77
Dimorphic fungal osteoarticular infections. Eur J Clin Microbiol Infect Dis (2014) 0.75
In vitro antifungal susceptibility profile and correlation of mycelial and yeast forms of molecularly characterized Histoplasma capsulatum strains from India. Antimicrob Agents Chemother (2014) 0.75
Successful treatment of osseous blastomycosis without pulmonary or disseminated disease and review of the literature. Diagn Microbiol Infect Dis (2014) 0.75
David and Goliath: chemical perturbation of eukaryotes by bacteria. J Ind Microbiol Biotechnol (2015) 0.75
Large Scale Evaluation of in vitro Amphotericin B, Triazole, and Echinocandin activity against Coccidioides species from United States Institutions. Antimicrob Agents Chemother (2017) 0.75
Amphotericin B: 30 years of clinical experience. Rev Infect Dis (1990) 5.82
Multicenter evaluation of proposed standardized procedure for antifungal susceptibility testing of filamentous fungi. J Clin Microbiol (1997) 5.64
In vitro activity of the new triazole voriconazole (UK-109,496) against opportunistic filamentous and dimorphic fungi and common and emerging yeast pathogens. J Clin Microbiol (1998) 5.13
In vitro susceptibilities of Candida bloodstream isolates to the new triazole antifungal agents BMS-207147, Sch 56592, and voriconazole. Antimicrob Agents Chemother (1998) 3.06
Trichosporon beigelii, an emerging pathogen resistant to amphotericin B. J Clin Microbiol (1990) 2.99
In vitro amphotericin B resistance in clinical isolates of Aspergillus terreus, with a head-to-head comparison to voriconazole. J Clin Microbiol (1999) 2.82
In vitro studies of activity of voriconazole (UK-109,496), a new triazole antifungal agent, against emerging and less-common mold pathogens. Antimicrob Agents Chemother (1997) 2.75
Comparative in-vitro activity of voriconazole (UK-109,496) and six other antifungal agents against clinical isolates of Scedosporium prolificans and Scedosporium apiospermum. J Antimicrob Chemother (1999) 2.74
Do in vitro susceptibility data predict the microbiologic response to amphotericin B? Results of a prospective study of patients with Candida fungemia. J Infect Dis (1998) 2.61
In vitro evaluation of voriconazole against some clinically important fungi. Antimicrob Agents Chemother (1997) 2.27
In-vitro activity of voriconazole, itraconazole and amphotericin B against filamentous fungi. J Antimicrob Chemother (1998) 1.98
Lipid formulations of amphotericin B: clinical efficacy and toxicities. Clin Infect Dis (1998) 1.91
In vitro efficacy and fungicidal activity of voriconazole against Aspergillus and Fusarium species. Eur J Clin Microbiol Infect Dis (1998) 1.71
In vitro comparative efficacy of voriconazole and itraconazole against fluconazole-susceptible and -resistant Cryptococcus neoformans isolates. Antimicrob Agents Chemother (1998) 1.69
In-vitro activities of amphotericin B, itraconazole and voriconazole against 150 clinical and environmental Aspergillus fumigatus isolates. J Antimicrob Chemother (1998) 1.27
In-vitro activity of voriconazole against Aspergillus spp. and comparison with itraconazole and amphotericin B. J Antimicrob Chemother (1998) 1.14
In vitro activity of voriconazole against Candida species. Diagn Microbiol Infect Dis (1998) 1.08
Role of azoles in antifungal therapy. Clin Infect Dis (1996) 1.00
Evaluation of the BACTEC radiometric method for recovery of mycobacteria and drug susceptibility testing of Mycobacterium tuberculosis from acid-fast smear-positive specimens. J Clin Microbiol (1983) 10.49
Enhanced differentiation of isolates of Candida albicans using a modified resistogram method. Mykosen (1982) 7.04
Quality control guidelines for National Committee for Clinical Laboratory Standards recommended broth macrodilution testing of amphotericin B, fluconazole, and flucytosine. J Clin Microbiol (1995) 6.02
Multicenter evaluation of proposed standardized procedure for antifungal susceptibility testing of filamentous fungi. J Clin Microbiol (1997) 5.64
Itraconazole resistance in Aspergillus fumigatus. Antimicrob Agents Chemother (1997) 4.75
Antifungal susceptibility testing: practical aspects and current challenges. Clin Microbiol Rev (2001) 4.49
Fluconazole resistance in Candida glabrata. Lancet (1988) 4.05
Fluconazole resistance in Candida glabrata. Antimicrob Agents Chemother (1993) 4.04
Trends in mortality due to invasive mycotic diseases in the United States, 1980-1997. Clin Infect Dis (2001) 3.68
Multisite reproducibility of colorimetric broth microdilution method for antifungal susceptibility testing of yeast isolates. J Clin Microbiol (1994) 3.46
Correlation between in-vitro susceptibility testing to itraconazole and in-vivo outcome of Aspergillus fumigatus infection. J Antimicrob Chemother (1997) 3.40
Standardized susceptibility testing of fluconazole: an international collaborative study. Antimicrob Agents Chemother (1992) 3.19
Resistogram method for differentiation of strains of Candida albicans. J Appl Bacteriol (1979) 2.97
Correlation of MIC with outcome for Candida species tested against voriconazole: analysis and proposal for interpretive breakpoints. J Clin Microbiol (2006) 2.86
Chromoblastomycosis and phaeohyphomycosis: new concepts, diagnosis, and mycology. J Am Acad Dermatol (1983) 2.84
Emergence of azole drug resistance in Candida species from HIV-infected patients receiving prolonged fluconazole therapy for oral candidosis. J Antimicrob Chemother (1995) 2.83
Vaginal candidiasis and the role of the digestive tract as a source of infection. Br J Obstet Gynaecol (1975) 2.76
In vitro studies of activity of voriconazole (UK-109,496), a new triazole antifungal agent, against emerging and less-common mold pathogens. Antimicrob Agents Chemother (1997) 2.75
Evaluation of YeastIdent and Uni-Yeast-Tek yeast identification systems. J Clin Microbiol (1987) 2.74
Aspergillus antigen latex test for diagnosis of invasive aspergillosis. Lancet (1991) 2.59
Storage of stock cultures of filamentous fungi, yeasts, and some aerobic actinomycetes in sterile distilled water. Appl Microbiol (1974) 2.50
Evaluation of the updated Vitek yeast identification data base. J Clin Microbiol (1990) 2.45
In-vitro resistance to imidazole antifungals in Candida albicans. J Antimicrob Chemother (1984) 2.43
Candida dubliniensis fungemia: the first four cases in North America. Emerg Infect Dis (2000) 2.34
Mechanisms and clinical impact of antifungal drug resistance. J Med Vet Mycol (1994) 2.32
Incidence of invasive aspergillosis following hematopoietic stem cell and solid organ transplantation: interim results of a prospective multicenter surveillance program. Med Mycol (2005) 2.29
Molecular biological characterization of an azole-resistant Candida glabrata isolate. Antimicrob Agents Chemother (1997) 2.27
In vitro evaluation of voriconazole against some clinically important fungi. Antimicrob Agents Chemother (1997) 2.27
Recent taxonomic developments and changes in medical mycology. Annu Rev Microbiol (1980) 2.25
Quantitation of Candida albicans ergosterol content improves the correlation between in vitro antifungal susceptibility test results and in vivo outcome after fluconazole treatment in a murine model of invasive candidiasis. Antimicrob Agents Chemother (2000) 2.22
Azole resistance in Candida albicans. J Med Vet Mycol (1986) 2.17
Emerging agents of phaeohyphomycosis: pathogenic species of Bipolaris and Exserohilum. J Clin Microbiol (1986) 2.17
In-vitro activity of voriconazole, itraconazole and amphotericin B against filamentous fungi. J Antimicrob Chemother (1998) 1.98
Typing of Candida albicans. J Hosp Infect (1984) 1.93
Clinical pharmacokinetics of systemic antifungal drugs. Clin Pharmacokinet (1983) 1.88
Lacazia loboi gen. nov., comb. nov., the etiologic agent of lobomycosis. J Clin Microbiol (1999) 1.86
Comparison of E-test and broth microdilution methods for antifungal drug susceptibility testing of molds. J Clin Microbiol (1999) 1.85
Pharmacokinetics of ketoconazole in normal subjects. J Antimicrob Chemother (1981) 1.84
Multicenter evaluation of Microring YT, a new method of yeast identification. J Clin Microbiol (1990) 1.83
Evaluation of the Baxter-MicroScan 4-hour enzyme-based yeast identification system. J Clin Microbiol (1991) 1.76
Epidemiology, clinical manifestations, and therapy of infections caused by dematiaceous fungi. J Chemother (2003) 1.75
In vitro testing of susceptibilities of filamentous ascomycetes to voriconazole, itraconazole, and amphotericin B, with consideration of phylogenetic implications. J Clin Microbiol (1998) 1.71
Computer-assisted rapid enzyme-linked immunosorbent assay (ELISA) in the serological diagnosis of aspergillosis. J Immunol Methods (1983) 1.70
Epidemiological investigation of patients with vulvovaginal candidosis. Application of a resistogram method for strain differentiation of Candida albicans. Br J Vener Dis (1979) 1.70
Trends in antifungal drug susceptibility of Cryptococcus neoformans isolates in the United States: 1992 to 1994 and 1996 to 1998. Antimicrob Agents Chemother (2001) 1.70
Clinical and mycological spectra of Wangiella dermatitidis infections. Mycoses (1994) 1.69
Nutritional physiology and taxonomy of human-pathogenic Cladosporium-Xylohypha species. J Med Vet Mycol (1996) 1.67
A randomized controlled trial of itraconazole versus fluconazole for the prevention of fungal infections in patients with haematological malignancies. U.K. Multicentre Antifungal Prophylaxis Study Group. Br J Haematol (1999) 1.66
Scedosporium inflatum, an emerging pathogen. J Clin Microbiol (1988) 1.54
Pathology of Penicillium marneffei. An emerging acquired immunodeficiency syndrome-related pathogen. Arch Pathol Lab Med (1997) 1.53
Bioassays for itraconazole blood levels: an interlaboratory collaborative study. J Antimicrob Chemother (1999) 1.52
Evaluation of the AUXACOLOR system, a new method of clinical yeast identification. J Clin Pathol (1995) 1.51
Preparation of temporary or permanent mounts of microfungi with undisturbed conidia. Mycologia (1974) 1.51
Fungal nail disease: a guide to good practice (report of a Working Group of the British Society for Medical Mycology). BMJ (1995) 1.50
Comparison of a new commercial colorimetric microdilution method with a standard method for in-vitro susceptibility testing of Candida spp. and Cryptococcus neoformans. J Antimicrob Chemother (1998) 1.50
Lack of correlation of in vitro amphotericin B susceptibility testing with outcome in a murine model of Aspergillus infection. J Antimicrob Chemother (2000) 1.50
Azole drug resistance in Candida species. J Med Microbiol (1992) 1.49
Detection of fungi in cerebrospinal fluid. Am J Med (1983) 1.48
Infections due to Xylohypha bantiana (Cladosporium trichoides). Rev Infect Dis (1989) 1.45
Scedosporium inflatum: clinical spectrum of a newly recognized pathogen. J Infect Dis (1990) 1.44
Effect of simultaneous oral and vaginal treatment on the rate of cure and relapse in vaginal candidosis. Br J Vener Dis (1979) 1.44
Modified response to ketoconazole of Candida albicans from a treatment failure. Lancet (1983) 1.43
Treatment of hepatic candidosis with liposomal amphotericin B in patient with acute leukaemia. Lancet (1991) 1.42
Ability of RapID Yeast Plus System to identify 304 clinically significant yeasts within 5 hours. J Clin Microbiol (1996) 1.41
Molecular epidemiological study of Aspergillus fumigatus in a bone marrow transplantation unit by PCR amplification of ribosomal intergenic spacer sequences. J Clin Microbiol (1998) 1.37
Gastrointestinal basidiobolomycosis in Arizona: clinical and epidemiological characteristics and review of the literature. Clin Infect Dis (2001) 1.36
Management of persistent vulvo vaginal candidosis due to azole-resistant Candida glabrata. Genitourin Med (1993) 1.35
Multiple dose pharmacokinetics of ketoconazole and their effects on antipyrine kinetics in man. J Antimicrob Chemother (1983) 1.34
Influence of food on the pharmacokinetics of ketoconazole. Antimicrob Agents Chemother (1984) 1.31
Comparison of in vitro antifungal activities of free and liposome-encapsulated nystatin with those of four amphotericin B formulations. Antimicrob Agents Chemother (1998) 1.31
Evaluation of Abbott Quantum II yeast identification system. J Clin Microbiol (1985) 1.30
Fusarium moniliforme, a new mycetoma agent. Restudy of a European case. Eur J Epidemiol (1985) 1.30
Taxonomic and nomenclatural evaluation of the genera Candida and Torulopsis. J Clin Microbiol (1984) 1.29
Azole drug resistance in yeasts. J Antimicrob Chemother (1995) 1.28
Intra- and interlaboratory study of a method for testing the antifungal susceptibilities of dermatophytes. J Clin Microbiol (2004) 1.26
Guidelines for the investigation of invasive fungal infections in haematological malignancy and solid organ transplantation. British Society for Medical Mycology. Eur J Clin Microbiol Infect Dis (1997) 1.25
Isolation of fungal rDNA from bottlenose dolphin skin infected with Loboa loboi. Med Mycol (1998) 1.24
Rapid enzyme-linked immunosorbent assay (ELISA) for Aspergillus fumigatus antibodies. J Clin Pathol (1982) 1.24
Report of the first human case of lobomycosis in the United States. J Clin Microbiol (2000) 1.22
Viability of fungal cultures maintained at -70 degrees C. J Clin Microbiol (1992) 1.22
Reclassification of Cladosporium bantianum in the genus Xylohypha. J Clin Microbiol (1986) 1.22
Comparison of the API Candida system with the AUXACOLOR system for identification of common yeast pathogens. J Clin Microbiol (1999) 1.21
Resistogram typing of Candida albicans isolates from oral and cutaneous sites in irradiated patients. Sabouraudia (1985) 1.20
Multiple dose pharmacokinetics of an oral solution of itraconazole in autologous bone marrow transplant recipients. J Antimicrob Chemother (1994) 1.20
Clinical pharmacokinetics of ketoconazole. Clin Pharmacokinet (1988) 1.20
In vitro activity of voriconazole against selected fungi. Med Mycol (1998) 1.19
Use of the Pastorex aspergillus antigen latex agglutination test for the diagnosis of invasive aspergillosis. J Clin Pathol (1995) 1.18
Disseminated Conidiobolus infection with endocarditis in a cocaine abuser. Arch Pathol Lab Med (1990) 1.17
Infections caused by dematiaceous fungi: chromoblastomycosis and phaeohyphomycosis. Infect Dis Clin North Am (1988) 1.17
Comparison of the multiple dose pharmacokinetics of two formulations of itraconazole during remission induction for acute myeloblastic leukaemia. J Antimicrob Chemother (1991) 1.17
Azole drug resistance as a cause of clinical relapse in AIDS patients with cryptococcal meningitis. Int J STD AIDS (1996) 1.16
Counterpoint: invasive aspergillosis and the environment--rethinking our approach to prevention. Clin Infect Dis (2001) 1.15
Constitutive melanin in the cell wall of the etiologic agent of Lobo's disease. Rev Inst Med Trop Sao Paulo (1999) 1.15
Evaluation of a new slide latex agglutination test for diagnosis of vaginal candidosis. Eur J Clin Microbiol (1987) 1.14
Multiple dose pharmacokinetics of an oral solution of itraconazole in patients receiving chemotherapy for acute myeloid leukaemia. J Antimicrob Chemother (1995) 1.14
Fusarium infection in burned patients. Am J Clin Pathol (1981) 1.13